InterShunt
MN - FridleyBiotechnology
Focus: InterShunt is a public biotechnology company focused on minimally invasive interarterial shunt technology for cardiovascular disease, particularly heart failure management. The company operates as a specialized device-focused biotech with a focused therapeutic pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About InterShunt
AI assessmentNot HiringNo open roles listed right now. Follow InterShunt to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PAS-C System
Heart FailureClinical Trials (1)
NCT06859970An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
N/AHelp build intelligence for InterShunt
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.